Medications prescribed, since 2004 (entire cohort)
| Medication | Cohort (n=253) |
| Anticoagulation (%) | |
| No anticoagulant medications | 58.5 |
| Warfarin | 20.2 |
| Antiplatelet | 13.8 |
| Novel anticoagulant | 0.8 |
| Warfarin and antiplatelet | 2.0 |
| Dual antiplatelet | 0.4 |
| Novel anticoagulant and aspirin | 0.4 |
| Previous warfarin | 2.4 |
| Previous aspirin | 1.6 |
| Digoxin (%) | 11.9 |
| Calcium channel blockers (%) | 2.0 |
| Diuretics (%) | 32.3 |
| Exposure to advanced therapy (%) | 71.9 |
| Current number of advanced therapies (%) | |
| 0 | 30.8 |
| 1 | 49.4 |
| 2 | 19.4 |
| 3 | 0.4 |
| Combination therapy (n=50) | % (number of subjects) |
| Bosentan and sildenafil | 68 (34/50) |
| Macitentan and sildenafil | 26 (13/50) |
| Macitentan and tadalafil | 2 (1/50) |
| Sildenafil and prostacyclins | 2 (1/50) |
| Sildenafil, macitentan and prostacyclins | 2 (1/50) |
Previous warfarin: subjects treated with warfarin during the study but ceased before time of last review; previous aspirin: subjects treated with aspirin during the study but therapy ceased before time of last review; combination therapy: the subset of patients on more than one advanced therapy (50 subjects). Data available in 100% of subjects for each variable.